SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

BeiGene to Hold Conference Call and Webcast on September 8, 2019 at 7:00 p.m. ET to Provide Corporate Update
[September 08, 2019]

BeiGene to Hold Conference Call and Webcast on September 8, 2019 at 7:00 p.m. ET to Provide Corporate Update


CAMBRIDGE, Mass. and BEIJING, China, Sept. 08, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, announced that the company will hold a conference call and webcast on Sunday, September 8, 2019, at 7:00 p.m. ET | Monday, September 9, 2019, at 7:00 a.m. Hong Kong time, prior to the open of trading on the Hong Kong Stock Exchange. On the call, Company management will provide information related to a recent short seller report commenting on the Company’s operations.

Conference Call and Webcast Information
Investors and analysts are invited to join the conference call using the following dial-in information:
U.S. Toll-Free: (844) 461-9930
Hong Kong: 5819-4851
China: 400-682-8609
Conference ID: 7797578

A live webcast of the conference call can be accessed from the investors setion of BeiGene’s website at  http://ir.beigene.com/ or http://hkexir.beigene.com. An archived replay will be available two hours after the event for 90 days.



About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,700 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.1


Investor Contact   Media Contact
Craig West   Liza Heapes
+1 857-302-5189   + 1 857-302-5663
ir@beigene.com   media@beigene.com

1 ABRAXANE®, REVLIMID® and VIDAZA® are registered trademarks of Celgene Corporation.

Primary Logo


[ Back To TMCnet.com's Homepage ]









Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2019 Technology Marketing Corporation. All rights reserved | Privacy Policy